Af­ter EMA flop, Puma takes Ner­l­ynx to Chi­na in new out-li­cens­ing deal

Fac­ing a like­ly road­block en­ter­ing the Eu­ro­pean mar­ket, Puma Biotech­nol­o­gy $PBYI is ink­ing a string of new deals in dif­fer­ent re­gions for its can­cer drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.